

1 **Ifakara MasterClasses: Lessons from leading experts on the battle against**
2 **malaria**

3 Ilinca I. Ciubotariu^{1*}, April Monroe^{2,3}, Nana Aba Williams^{4,5}, Sheila B. Ogoma⁶, Fredros
4 Okumu^{3*}

5 ¹ Department of Biological Sciences, Purdue University, West Lafayette, USA

6 ² Johns Hopkins Center for Communication Programs, Baltimore, USA

7 ³ Ifakara Health Institute, Ifakara, Tanzania

8 ⁴ MESA Alliance, Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain

9 ⁵ Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de
10 Barcelona, Barcelona, Spain

11 ⁶ PMI VectorLink Abt Associates, Nairobi, Kenya

12 * Correspondence: iciubota@purdue.edu (I. I. Ciubotariu), fredros@ihi.or.tz (F. Okumu)

13 **Authors' ORCID and Twitter information:**

14 Ilinca I. Ciubotariu, ORCID: 0000-0002-6549-0771, Twitter: @iliciub1

15 April Monroe, ORCID: 0000-0002-8959-6837, Twitter: @AprilCMonroe

16 Nana Aba Williams, ORCID: 0000-0003-3520-7573, Twitter: @NanaAbaWill

17 Sheila B. Ogoma, ORCID: 0000-0002-4063-6762, Twitter: @Ogoma_S

18 Fredros Okumu, ORCID: 0000-0003-2731-5654, Twitter: @Fredros_Inc

19

20 **Abstract**

21 Bringing together the global community is vital for continued progress in the fight

22 against malaria. The Ifakara MasterClasses consist of discussions with experts that

23 allow for applied understanding of specific subjects related to malaria control. They

24 enable researchers, post-graduate students, National Malaria Program officials, and

25 malaria advocates to engage in the same virtual room to share best practices in malaria

26 control. In this *TrendsTalk*, the organizers, hosts, and some participant researchers

27 present a synthesis of five key MasterClasses held to emphasize their mission of

28 promoting essential scientific discourse on malaria and its control by bringing together

29 world-leading experts to discuss technical knowledge and experiences with a wide

30 audience.

31

48 **Overview of the Ifakara MasterClasses**

49 The Ifakara MasterClasses in public health and medical entomology provide a platform
50 for world-leading experts in malaria and its control to share their technical knowledge
51 and experiences with researchers, post-graduate students, National Malaria Program
52 (NMP) officials, and malaria advocates. These classes are conducted in the form of
53 informational interviews and conversations. The web conferences occur typically twice
54 per month on Wednesdays or Thursdays, with approximately 150-350 people joining
55 live by Zoom and asking additional questions via the chat box. All classes, starting from
56 edition 16, were streamed live on YouTube ⁱ.

57 Advance reviews of the experts' research are carried out and related works are
58 compiled, and illustrative slides to anchor the discussions are created by the organizer
59 and host Dr. Fredros Okumu (Ifakara Health Institute, Tanzania) and co-hosts, Dr. Nana
60 Aba Williams (MESA, ISGlobal, Spain) and Dr. Sheila Ogoma (PMI VectorLink Abt
61 Associates, Kenya). Each session is guided by a set of curated questions that stem
62 from scientific literature, policy documents, and program experience on a specific topic.
63 The questions aid the discussion with the technical experts invited to contribute to the
64 comprehensive and technical understanding of the chosen topic on malaria disease and
65 control. The sessions typically last about 150 minutes, with the expert/s speaking most
66 of that time, and the hosts probing for additional details where necessary.

67 Given their format, the sessions provide a platform for international experts, students,
68 and workers across the world to come together in one "room" and participate in real-
69 time to learn and have questions answered. These meetings, albeit voluntary and non-
70 funded, present a unique opportunity to highlight challenges and barriers that remain for

71 malaria elimination, as well as emphasize research priorities, and discuss future
72 partnerships and training.

73 Overall, the goal is to promote essential scientific discourse on malaria and its control
74 and to provide technical understanding of specific subjects for the audience. The
75 MasterClasses were created by Dr. Okumu in December 2020 and organically grew in
76 response to interest from the global malaria community. To date, 42 editions have been
77 completed (see supplementary **Table S1** for details).

78 This report presents insights from five of the MasterClasses to illustrate the value of the
79 platform for the broader community of malaria stakeholders. These sessions were
80 selected to highlight a multifaceted approach for malaria elimination, covering topics
81 ranging from control interventions to vaccine development. Key lessons from five guest
82 experts Prof. Brian M. Greenwood (London School of Tropical Medicine and Hygiene,
83 UK), Prof. Kevin Marsh (University of Oxford, UK), Prof. Stephen Hoffman (Sanaria Inc.,
84 USA), Prof. Adrian Hill (University of Oxford, UK), and Prof. Marcel Tanner (University
85 of Basel, Switzerland) are presented. Where relevant, specific references are made to
86 the key publications used to guide the expert discussions. The selected sessions
87 broadly cover important policy and Research and Development (R&D) agendas for
88 malaria.

89

90 **Voices of a quintet: Key lessons and big ideas from expert sessions on malaria**

91 *The long road to malaria elimination: A MasterClass with Prof. Brian M. Greenwood*

92 Prof. Greenwood discussed the history of malaria control efforts, noting that despite
93 steady progress and acceleration due to high-impact interventions, the disease still

94 claims hundreds of thousands of lives annually [1, 2]. He emphasized the need for
95 continued innovations and adaptations in malaria control strategies [3], as well as
96 sustained financial and political support, to achieve malaria elimination [1, 2]. He
97 highlighted the importance of research and development in combating malaria, citing
98 the successes of insecticide-treated bed nets (ITNs) and artemisinin-based combination
99 therapies (ACTs) as examples.

100 Prof. Greenwood also discussed some of the main challenges facing malaria elimination
101 efforts, including the emergence of drug-resistant strains of the malaria parasite and
102 insecticide-resistant mosquitoes [4]. He argued that surveillance systems are a critical
103 component of malaria control and elimination efforts, and must be sustained to address
104 the current and future challenges [5]:

105 “It isn’t an end to get your certificate [of elimination] from the World Health Organization
106 (WHO) Director General and then say malaria is done, we can do something else... that
107 [the effort] has to be kept. The battle continues...”

108 In addition, he outlined the importance of partnerships in malaria control, emphasizing
109 that the different parties involved should have coordinated efforts pursuing similar
110 targets [6]. He particularly encouraged epidemiologists and vector biologists to work
111 together, as well as governments, international organizations, and local communities.
112 Effective public engagement was also identified as crucial given that local knowledge
113 and participation can address local challenges. Finally, Prof. Greenwood discussed the
114 importance of sustained funding for malaria control efforts, noting that current levels
115 remain below the budgetary needs and that greater efficiencies can be achieved

116 through policies guided by science to prioritize the most effective interventions in
117 different settings:

118 “An important lesson, which can relate to any infectious disease, is that policy should be
119 guided by science. If data show that the thing that has been most effective in reducing
120 deaths and the burden in malaria has been the distribution of ITNs, then if you have
121 limited amount of money, and you believe the science and it has been done by
122 reputable people and ideally confirmed by other groups, then you should be putting the
123 resources into what the science tells you to do.”

124

125 *The big malaria questions: A MasterClass with Prof. Kevin Marsh*

126 In this session, Prof. Marsh shared his journey as a scientist before exploring various
127 topics related to malaria. He discussed the global trends in malaria control using real-life
128 examples from his work across Africa. He appreciated the current risks [3, 7] and
129 limitations such as the rise in artemisinin resistance [8], as well as the challenges in
130 understanding malaria immunology [9], which would be crucial for developing high
131 impact vaccines and therapeutics. He also discussed the impacts of current
132 interventions, such as expanded ITN coverage [10], and emphasized the importance of
133 health systems in controlling and reducing the malaria burden while also building a
134 strong foundation towards eventual malaria eradication.

135 Prof. Marsh also discussed the application of various control and prevention
136 mechanisms such as larvicides, ITNs, indoor residual spraying (IRS), mass drug
137 administration (MDA) [11] and seasonal malaria chemoprevention (SMC) [12]. He

138 particularly highlighted the importance of integrating different control options and the
139 need to apply basic biology of the disease to optimize its control in local settings:
140 “It comes back, as these things often do, to things we know very well – the importance
141 of integrated vector management, instead of a single approach...the important thing is
142 always to look at the biology of what one is to do. Does it fit here, in this circumstance?”

143 Prof. Marsh also discussed the timeline of research and development for malaria
144 eradication [13, 14], including progress on the vaccine front with RTS,S and the
145 potential of gene drives. He underscored the importance of capacity sharing in all
146 directions (as opposed to capacity building) and drawing on lessons of the past to
147 inform improved efforts. He encouraged the alignment of ongoing research with the key
148 questions that policymakers need answers to, rather than just academic interests. He
149 concluded by reiterating the importance of functioning health systems, continued R&D,
150 and greater investments towards malaria elimination and eradication:

151 “What we really need to do is to make sure that our research as a community, whether
152 we work on vaccines or drugs or community interventions or health systems, we need to
153 make sure that our research is very closely aligned to what are the key questions that
154 policymakers need answers to, not just what are we interested in as academic
155 research.”

156

157 *The enduring search for malaria vaccines: A MasterClass with Prof. Stephen Hoffman*

158 This session focused on the development of malaria vaccine candidates [15], including
159 RTS,S, the most advanced malaria vaccine [16] now recommended by the WHO for at-
160 risk children [17], and the whole sporozoite vaccines being developed by Sanaria, Inc..

161 Prof. Hoffman shared his journey in malaria research [18], then highlighted both the
162 basic principles and recent developments in creating vaccines for protozoan parasites in
163 contrast to other types of vaccines [19]. He described the current consensus roadmap
164 of the development of malaria vaccine technologies [20, 21] and highlighted the
165 importance of the RTS,S as the first vaccine against a human parasite, having been
166 approved for widespread use in areas of moderate to high *Plasmodium falciparum*
167 transmission. He however noted that while RTS,S vaccine was an enormous step
168 forward for the field [22], its efficacy was limited, with only 36% against symptomatic
169 malaria [23]. Prof. Hoffman emphasized that vaccines are incredibly powerful tools for
170 disease control and recognized the need to integrate them into ongoing malaria control
171 programs, including seasonal chemoprevention [24, 25], depending on local
172 transmission:

173 “Malaria is not just one disease from an epidemiological point of view. In some places
174 we have a long road ahead of us, where we will have to be hitting malaria with every
175 tool we potentially have, and in other areas we may actually be able to get to the point
176 of even elimination... We need new tools and vaccines are the most effective tools for
177 limiting infectious disease, but it doesn't obviate the need for other tools... it's [one
178 single vaccine] not a winner-take-all, it's too hard a problem and we need everybody's
179 efforts as we go forward...you will get knocked down over and over again by malaria – it
180 is a tough foe but we are making progress, inching forward every day and we have to
181 keep up the work.”

182 Prof. Hoffman then presented the innovative approaches that Sanaria Inc. has taken to
183 develop a metabolically active, non-replicating sporozoite vaccine [26], which has

184 shown promising results in clinical trials [27, 28]. In concluding his session, he
185 highlighted the importance of international collaboration and how this has contributed to
186 the development of this particular vaccine through the PfSPZ consortium. This example
187 highlights the scientific strides that can be made toward a common goal through
188 collaborative efforts and collective knowledge generation:

189 “Individuals from so many different organizations and different countries... I like to think
190 that it is a model for how we can really pursue global health and research together, as
191 one team, dedicated to solving enormously difficult and important problems.”

192

193 *The next malaria vaccine: A MasterClass with Prof. Adrian Hill*

194 In this session, Prof. Adrian Hill started by describing vaccination in the context of
195 Covid-19 [29] and transitioned to discussing the current state of malaria control [1],
196 emphasizing the need for new tools to complement existing interventions such as drugs
197 and insecticides. He noted that malaria vaccines could offer new opportunities for more
198 effective control, but described the difficulties experienced over the past century of
199 malaria vaccine research [30, 31]. He also discussed the recent delays in pre-
200 qualification by the Strategic Advisory Group of Experts on Immunization (SAGE) from
201 the WHO [32] of the new malaria vaccines with the identification of a non-trivial
202 increased female mortality signal [33]. He proceeded to describe the progress made in
203 developing and evaluating the R21 vaccine [34], an effort that he spearheaded from the
204 early 1990s, from vaccine design to protocol and implementation. The R21 vaccine is a
205 variant of the RTS,S that will likely be the second human malaria vaccine to be
206 approved. He highlighted some major similarities and differences between this vaccine

207 and RTS,S, in particular the higher efficacy of the R21 vaccine, which achieved 77% in
208 Phase 2 trials in West Africa [35] and the greater “manufacturability” of the R21
209 compared to RTS,S. Prof. Hill also highlighted the urgent need to address funding gaps
210 for the implementation of effective vaccines and the need to accelerate vaccine
211 regulatory processing and roll-out. He encouraged researchers, regulators, and public
212 health authorities to be more demanding of international organizations who support
213 malaria to do so in the present rather than in years’ time:

214 “...The sooner you start the more lives you save and believe me we have been waiting
215 for decades for malaria vaccines to be rolled out; let’s not waste another two or three
216 years after it’s available by fooling around to organize it, we are giving notice now –
217 these vaccines are coming. There’s going to be enough of them between the two
218 [RTS,S and R21] of them, and the challenge then is to use them as efficiently as
219 possible to save lives. And you don’t have to think too hard about doing other things,
220 you are doing those already, just bring the vaccine on top and see what the impact is.”

221 He acknowledged the potential advantage of combining vaccines with other
222 interventions in the field like SMC [36], or multi-stage vaccines which target different
223 parasite stages [37], and argued that these could accelerate progress toward
224 eliminating malaria [38]. Prof. Hill concluded by recognizing the importance of local
225 community involvement, education, and sharing research to accelerate vaccine supply
226 for malaria. He noted manufacturing of vaccines should be done in Africa to ensure self-
227 sufficiency and increase pipelines and access. He encouraged the momentum of
228 vaccinology in Africa and emphasized the need for continued investment in R&D to

229 address challenges in malaria elimination. Dr. Hill's final words left the session
230 attendees with motivation and further hope to continue the difficult research:
231 "It's fantastic to see more and more young African scientists demanding that they have
232 access to capacity... it's ridiculous having a lot of it done thousands of miles away so
233 my congratulations to everyone who is involved in this renaissance, if you like, of
234 vaccinology in Africa. Please keep the momentum going; money is coming in faster. It's
235 a long way to go but it's the right time."

236 At the time of this piece, recent data were released which showed that the R21/Matrix-M
237 achieved the WHO-specified efficacy goal of > 75%, and this ignited its regulatory
238 clearance for use in children aged 5-36 months in Ghana, followed by provisional
239 approval in Nigeria [39].

240

241 *Malaria strategies: A MasterClass with Prof. Marcel Tanner*

242 Prof. Tanner started the session by discussing the current strategies for malaria control,
243 including the use of vector control methods (mainly ITNs and IRS), and antimalarial
244 drugs. He noted that these strategies have led to significant reductions in malaria
245 incidence and mortality, but that progress has plateaued in recent years. Next, he
246 discussed the challenges facing malaria elimination [40], including the emergence of
247 drug-resistant malaria parasites and insecticide-resistant mosquitoes which threaten the
248 possibility of eradication [13]. He emphasized the need for continued investment in
249 research and development to address these challenges, as well as financing to develop
250 and evaluate new tools for malaria control such as monoclonal antibodies [41] or
251 vaccines [38]. He however also argued that while funding is crucial [3], efforts must

252 extend beyond just the amount of money. He particularly stressed the importance of
253 tailoring strategies to the local setting and investing in personnel development and
254 capacity building:

255 “It is not just the amount of money, but it is how you invest it...it is tailoring a strategy to
256 the local setting, which also entails that you are investing in personnel development,
257 capacity building, which are specifically needed...really going into investments so you
258 can build the capacity. Invest in a systemic approach. Understand the context, reconcile
259 the different needs, and focus on the key question.”

260 In this context, Prof. Tanner also discussed the importance of community engagement
261 and ownership in ensuring more impactful malaria interventions [42]. He notes that
262 engaging with affected communities and empowering them can be highly effective in
263 reducing malaria incidence. He also accentuated the need for collaboration and multi-
264 stakeholder partnerships bringing together researchers, policymakers, and affected
265 communities to develop comprehensive malaria control strategies [43]. Lastly, he put
266 forth his “mutual learning for change” idea:

267 “Being a scientist is carried by the three joys – the joy to discover [to actually do science
268 and ask questions], the joy to share [to be here in this webinar], the joy to see and be
269 involved in translation [to actually change something]... I am enthused by the fact that I
270 can also share my knowledge. It’s wonderful to share the data at any time because we
271 learn together to make a real difference. The science system must honor and reward
272 this type of attitude and not the monument-carving metric system. At least we should
273 adhere to the DORA principles [San Francisco Declaration on Research Assessment –
274 a set of recommendations designed for the purpose of ensuring the appropriate and

275 accurate evaluation of the quality and impact of scientific outputs [44]... much more
276 needs to be done and then we see changes.”

277

278 **Impact of the MasterClasses and next steps**

279 Overall, the Ifakara MasterClasses emphasize the urgent need for transformative efforts
280 to combat malaria and increased investments to accelerate the malaria elimination
281 agenda. In the five sessions highlighted, there was agreement that current
282 interventions, such as insecticide-treated bed nets and anti-malarial drugs, have
283 allowed for significant progress in reducing malaria deaths, but there is still much work
284 to be done. The development of effective malaria vaccines was discussed as a
285 promising strategy for reducing the burden of malaria, with a particular focus on recent
286 advances in the R21/Matrix-M vaccine. The experts emphasized the importance of
287 continued funding for research and development of new tools, as well as the need for
288 collaboration among international organizations, governments, and local communities to
289 effectively address the challenges of malaria control and elimination. Finally, there was
290 consensus on the call to action for increased investment in training and capacity sharing
291 for African scientists and healthcare workers, as well as for manufacturing vaccines in
292 Africa to increase access and self-sufficiency in the region.

293 MasterClasses provide a unique forum to explore challenges that remain for malaria
294 elimination, to emphasize research priorities, and discuss future partnerships and
295 training. In-depth discussions are centered around published scientific findings and
296 agendas, providing a review of how specific published work fits within the big picture of
297 a given topic of discussion. The sessions are free, virtual, and open to all, and bring

298 together a broad range of professionals from different background and at various stages
299 in their careers. The classes have expanded naturally, and participation has been
300 sustained at a high level, with experts from previous MasterClasses regularly joining as
301 participants in subsequent sessions.

302 The MasterClasses have opened doors for collaborations, and since the year 2022,
303 MESA, a malaria knowledge hub, contributes to the preparation and execution of these
304 sessions. MESA is a resource that gathers the malaria community to work
305 collaboratively towards a malaria-free world. MasterClasses may continue to evolve to
306 meet the needs of the global malaria community. Potential examples include collating
307 and organizing materials (such as content used for advanced review and final
308 PowerPoint slides) and making them accessible in one place, and further exploring
309 opportunities to effectively engage non-English speaking malaria professionals.
310 Moving forward, forums like Ifakara MasterClasses can play important roles in
311 democratizing technical discussions and providing platforms for engagement and cross-
312 fertilization of ideas needed in the fight against malaria.

313

314 **Resources**

315 ⁱ <https://www.youtube.com/@ifakarahealthinstitute/videos>

316

317 **References**

- 318 1 WHO (2022) World malaria report 2022. World Health Organization
319 <https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022>
320 2 WHO (2021) Global technical strategy for malaria 2016-2030, 2021 update.
321 <https://www.who.int/publications/i/item/9789240031357>
322 3 WHO (2015) Global technical strategy for malaria 2016–2030. Geneva: World Health Organization
323 https://www.who.int/malaria/areas/global_technical_strategy/en

- 324 4 Greenwood, B.M., *et al.* (2008) Malaria: progress, perils, and prospects for eradication. *The Journal of*
325 *Clinical Investigation* 118, 1266-1276
- 326 5 Greenwood, B. (2017) Elimination of malaria: halfway there. *Transactions of The Royal Society of*
327 *Tropical Medicine and Hygiene* 111, 1-2
- 328 6 Alonso, P.L., *et al.* (2011) A Research Agenda to Underpin Malaria Eradication. *PLOS Medicine* 8,
329 e1000406
- 330 7 Paton, R.S., *et al.* (2021) Malaria infection and severe disease risks in Africa. *Science* 373, 926-931
- 331 8 Balikagala, B., *et al.* (2021) Evidence of Artemisinin-Resistant Malaria in Africa. *New England Journal of*
332 *Medicine* 385, 1163-1171
- 333 9 Langhorne, J., *et al.* (2008) Immunity to malaria: more questions than answers. *Nature Immunology* 9,
334 725-732
- 335 10 Bhatt, S., *et al.* (2015) The effect of malaria control on *Plasmodium falciparum* in Africa between
336 2000 and 2015. *Nature* 526, 207-211
- 337 11 WHO (2017) Mass drug administration for falciparum malaria: a practical field manual. Geneva:
338 World Health Organization <https://www.who.int/publications/i/item/9789241513104>
- 339 12 Baba, E., *et al.* (2020) Effectiveness of seasonal malaria chemoprevention at scale in west and central
340 Africa: an observational study. *The Lancet* 396, 1829-1840
- 341 13 WHO (2020) Malaria eradication: benefits, future scenarios & feasibility. Geneva: World Health
342 Organization <https://www.who.int/publications/i/item/9789240003675>
- 343 14 Feachem, R.G.A., *et al.* (2019) Malaria eradication within a generation: ambitious, achievable, and
344 necessary. *The Lancet* 394, 1056-1112
- 345 15 Schwartz, L., *et al.* (2012) A review of malaria vaccine clinical projects based on the WHO rainbow
346 table. *Malaria Journal* 11, 11
- 347 16 Zavala, F. (2022) RTS,S: the first malaria vaccine. *The Journal of Clinical Investigation* 132
- 348 17 WHO (2021) WHO recommends groundbreaking malaria vaccine for children at risk.
349 [https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-](https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk)
350 [children-at-risk](https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk)
- 351 18 Mullins, L. (2013) Dr. Hoffman vs. the Mosquito. [https://www.washingtonian.com/2013/10/23/dr-](https://www.washingtonian.com/2013/10/23/dr-hoffman-vs-the-mosquito/)
352 [hoffman-vs-the-mosquito/](https://www.washingtonian.com/2013/10/23/dr-hoffman-vs-the-mosquito/)
- 353 19 Pollard, A.J. and Bijker, E.M. (2021) A guide to vaccinology: from basic principles to new
354 developments. *Nature Reviews Immunology* 21, 83-100
- 355 20 WHO (2013) Malaria Vaccine Technology Roadmap. Geneva: World Health Organization
356 <https://www.who.int/publications/m/item/malaria-vaccine-technology-roadmap>
- 357 21 malERA (2011) A Research Agenda for Malaria Eradication: Vaccines. *PLOS Medicine* 8, e1000398
- 358 22 Beeson, J.G., *et al.* (2022) The RTS,S malaria vaccine: Current impact and foundation for the future.
359 *Science Translational Medicine* 14, eabo6646
- 360 23 CTP (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in
361 infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. *The*
362 *Lancet* 386, 31-45
- 363 24 Greenwood, B., *et al.* (2017) Seasonal vaccination against malaria: a potential use for an imperfect
364 malaria vaccine. *Malaria Journal* 16, 182
- 365 25 Thompson, H.A., *et al.* (2022) Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical
366 modelling study. *The Lancet Global Health* 10, e1782-e1792
- 367 26 Hoffman, S.L., *et al.* (2010) Development of a metabolically active, non-replicating sporozoite vaccine
368 to prevent *Plasmodium falciparum* malaria. *Human Vaccines* 6, 97-106
- 369 27 Mordmüller, B., *et al.* (2017) Sterile protection against human malaria by chemoattenuated PfSPZ
370 vaccine. *Nature* 542, 445-449

- 371 28 Richie, T.L., *et al.* (2015) Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria
372 vaccines. *Vaccine* 33, 7452-7461
- 373 29 Watson, O.J., *et al.* (2022) Global impact of the first year of COVID-19 vaccination: a mathematical
374 modelling study. *The Lancet Infectious Diseases* 22, 1293-1302
- 375 30 Hill, A.V.S. (2011) Vaccines against malaria. *Philosophical Transactions of the Royal Society B:*
376 *Biological Sciences* 366, 2806-2814
- 377 31 Mance, H. (2022) Adrian Hill: 'This is the breakthrough tool — vaccines against malaria'.
378 <https://www.ft.com/content/ff5e9c24-4a63-44cb-b526-00e607a07abe>
- 379 32 White, M.T., *et al.* (2015) Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for
380 duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. *The*
381 *Lancet Infectious Diseases* 15, 1450-1458
- 382 33 Klein, S.L., *et al.* (2016) RTS,S Malaria Vaccine and Increased Mortality in Girls. *mBio* 7, e00514-00516
- 383 34 Collins, K.A., *et al.* (2017) Enhancing protective immunity to malaria with a highly immunogenic virus-
384 like particle vaccine. *Scientific Reports* 7, 46621
- 385 35 Dattoo, M.S., *et al.* (2022) Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical
386 malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
387 *The Lancet Infectious Diseases* 22, 1728-1736
- 388 36 Greenwood, B., *et al.* (2021) Combining malaria vaccination with chemoprevention: a promising new
389 approach to malaria control. *Malaria Journal* 20, 361
- 390 37 Hill, A.V.S., *et al.* (2014) Towards a multi-antigen multi-stage malaria vaccine. *Malaria Journal* 13, O31
- 391 38 Penny, M.A., *et al.* (2020) Future use-cases of vaccines in malaria control and elimination. *Parasite*
392 *Epidemiology and Control* 10, e00145
- 393 39 Oxford (2023) R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory
394 clearance for use in Ghana. [https://www.ox.ac.uk/news/2023-04-13-r21matrix-m-malaria-vaccine-](https://www.ox.ac.uk/news/2023-04-13-r21matrix-m-malaria-vaccine-developed-university-oxford-receives-regulatory)
395 [developed-university-oxford-receives-regulatory](https://www.ox.ac.uk/news/2023-04-13-r21matrix-m-malaria-vaccine-developed-university-oxford-receives-regulatory)
- 396 40 Alonso, P.L. and Tanner, M. (2013) Public health challenges and prospects for malaria control and
397 elimination. *Nature Medicine* 19, 150-155
- 398 41 Gaudinski, M.R., *et al.* (2021) A Monoclonal Antibody for Malaria Prevention. *New England Journal of*
399 *Medicine* 385, 803-814
- 400 42 WHO (2018) High burden to high impact: a targeted malaria response. Geneva: World Health
401 Organization <https://www.who.int/publications/i/item/WHO-CDS-GMP-2018.25>
- 402 43 Tanner, M. and Meier, L. (2019) Viewpoint: Parasites and partnerships. *Parasite Epidemiology and*
403 *Control* 4, e00086
- 404 44 DORA (2017) San Francisco Declaration on Research Assessment. <https://sfdora.org/read/>
- 405

Supplementary file

Ifakara MasterClasses: Lessons from leading experts on the battle against malaria

Ilinca I. Ciubotariu^{1*}, April Monroe^{2,3}, Nana Aba Williams^{4,5}, Sheila B. Ogoma⁶, Fredros Okumu^{3*}

¹ Department of Biological Sciences, Purdue University, West Lafayette, USA

² Johns Hopkins Center for Communication Programs, Baltimore, USA

³ Ifakara Health Institute, Ifakara, Tanzania

⁴ MESA Alliance, Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain

⁵ Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain

⁶ PMI VectorLink Abt Associates, Nairobi, Kenya

* Correspondence: iciubota@purdue.edu (I. I. Ciubotariu), fredros@ihi.or.tz (F. Okumu)

Table S1. A list of the first 42 editions of Ifakara MasterClasses.

TITLE

Reviewing the World Malaria Report 2022 & Priority R&D for Elimination

Anopheles stephensi in Africa: a Masterclass with Global Experts & In-country Practitioners

Preventive Therapies for Malaria [including a case study of Tanzania's evaluation of preventive therapies]

The Next Malaria Vaccine: A MasterClass with Prof. Adrian Hill

The Mosquitoes Must Surrender: a MasterClass with IVCC & Partners

New Nets & New Sprays for Malaria Control: A MasterClass with Prof. Natacha Protopopoff, Corine Ngufor, Joe Wagman, Seth Irish, Abraham Mnzava &

The Big Malaria Questions: A MasterClass with Prof. Kevin Marsh

Reviewing the 2021 World Malaria Report: a Masterclass with Pedro Alonso, Abdisalan Noor, Jennifer Gardy & Richard Steketee

Infected But Not Sick: a MasterClass with Profs. Chris Drakeley & Teun Bousema

Costs & Coverage of [Malaria] Control: a MasterClass with Profs. H. Koenker, Yukich & M. Erskine

Sustaining the [Malaria] Gains: a MasterClass with Profs. Thomas Churcher & Ellie Sherrard Smith

Malaria Strategies: A MasterClass with Prof. Marcel Tanner

Malaria Meds: a MasterClass with Profs. Timothy Wells, Pierre Hugo, George Jagoe & Abdoulaye Djimde

Vectors Asia, Africa & the Americas: S. Manguin, I. Vythilingam, Y. Rubio Palis, L. Koekemoer

Malaria Maps and Models: a MasterClass with Profs. S. Bhatt, S. Kiware, L. Tusting & J. Gerardin

Two Billion Mosquito Nets & Counting: a MasterClass with Prof. Christian Lengeler

The Enduring Search for Malaria Vaccines: a MasterClass with Prof. Stephen Hoffman (Sanaria Inc.)

Genomic Surveillance: With Profs. DWirth, S Volkman, D Ishengoma, A Miles & M Lawniczak

Malaria Dalenda Est: a MasterClass with Drs. Phillip Welkhoff, Helen Jamet & Meera Venkatesan

Fixed, Few & Findable: a MasterClass with Profs. H Kafy, P Dambach, P Dechant & S Majambere

Aedes & Stephensi: a MasterClass with Profs. Peter Ryan, Basile Kamgang & Fitsum G. Tadesse

A Thousand Lives a Day: a MasterClass with Profs. Pedro Alonso, Patrick Kachur & Elizabeth Juma

The Mosquitoes Must Die: a MasterClass with Profs. Hilary Ranson & Corine Ngufor

There's a Gene in my Mosquitoes: a MasterClass with Profs. Austin Burt, Tony Nolan & A. Diabate

The Elegant Math of Malaria Transmission & Its Control: a MasterClass with Prof. David L Smith

The Long Road to Malaria Elimination: a MasterClass with Prof. Brian M Greenwood

Vector Surveillance 101: a MasterClass with Profs. Tom Burkot & Tanya Russell

The Mosquitoes Have Refused to Die: A MasterClass with Prof. Charles Wondji

Eaves, Marshes, and Mosquitoes: a MasterClass with Prof. Steve Lindsay

The MalariaSphere: a MasterClass with Dr. Bart Geert Jan Knols

Funestus 101: Opportunities for a more realistic malaria fight: a MasterClass with Prof. Jo Lines
The District Entomologist: Strengthening Local Capacity for Malaria Vector Surveillance: a MasterClass with District Malaria Surveillance
The District Entomologist: Why Malaria-endemic Countries Must Train More Field Entomologists: A masterclass with Prof Abraham Lines and Dots: a MasterClass with Prof. Abdisalan Noor
Mosquitoes, Monkeys & Disease: A Masterclass with Prof. Indra Vythilingam
Vector wars: why malaria control must exploit the biology of Anopheles mosquitoes: A Masterclass with Prof. Leonard Mboera
Taxa Woes Fallacy of Malaria Control without Field Entomologists Expert: a Masterclass with Prof Maureen Coetzee
Treating the Fabric: how early entomologists harnessed biology to revolutionize malaria control: a Masterclass with Prof. Pierre Carnevale
Protective atmospheres how malaria control can transition from pesticides: a MasterClass with Prof. Willem Takken Part 2
Protective atmospheres how malaria control can transition from pesticides: a MasterClass with Prof. Willem Takken Part 1
The Rise & Fall of Medical Entomology: Reflections from Africa, Asia & The Americas: a MasterClass with Prof. Derek Charlwood
The Land of Gambiae: Malaria Entomology in the Days Before ITNs: a MasterClass with Prof Graham White

EDITION	DATE PUBLISHED ON YOUTUBE	EXTERNAL LINK	MESA LINK		
42	16-Feb-2023	https://www.youtube.com/watch	https://mesamalaria.org/reso		
41	26-Jan-2023	https://www.youtube.com/watch	https://mesamalaria.org/reso		
39 & 40	15-Dec-2022	https://www.youtube.com/watch	https://mesamalaria.org/reso		
38	4-Aug-2022	https://www.youtube.com/watch	https://mesamalaria.org/reso		
37	26-May-2022	https://www.youtube.com/watch	https://mesamalaria.org/reso		
36	12-May-2022	https://www.youtube.com/watch	https://mesamalaria.org/reso		
35	14-Apr-2022	https://www.youtube.com/watch	https://mesamalaria.org/reso		
34	15-Dec-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
33	28-Oct-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
32	21-Oct-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
31	14-Oct-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
30	12-Aug-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
29	5-Aug-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
28	15-Jul-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
27	1-Jul-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
26	24-Jun-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
25	3-Jun-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
24	20-May-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
23	12-May-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
22	5-May-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
21	21-Apr-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
20	8-Apr-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
19	31-Mar-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
18	24-Mar-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
17	10-Mar-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
16	3-Mar-2021	https://www.youtube.com/watch	https://mesamalaria.org/reso		
15	24-Feb-2021	Online Link Pending	Online Link Pending		
14	17-Feb-2021	Online Link Pending	Online Link Pending		
13	11-Feb-21	Online Link Pending	Online Link Pending		
12	5-Feb-2021	Online Link Pending	Online Link Pending		

11	28-Jan-21	Online Link Pending	Online Link Pending
10b	10-Oct-2021	No Recording	No Recording
10a	9-Dec-2020	Online Link Pending	Online Link Pending
9	14-Jan-21	Online Link Pending	Online Link Pending
8	13-Jan-2021	Online Link Pending	Online Link Pending
6	10-Dec-2020	Online Link Pending	Online Link Pending
5	8-Dec-2020	https://www.youtube.com/watch?v=...	https://mesamalaria.org/resolutions/...
4	4-Dec-2020	https://www.youtube.com/watch?v=...	https://mesamalaria.org/resolutions/...
3b	18-Dec-2020	https://www.youtube.com/watch?v=...	https://mesamalaria.org/resolutions/...
3a	3-Dec-2020	https://www.youtube.com/watch?v=...	https://mesamalaria.org/resolutions/...
2	2-Dec-2020	https://www.youtube.com/watch?v=...	https://mesamalaria.org/resolutions/...
1	1-Dec-2020	https://www.youtube.com/watch?v=...	https://mesamalaria.org/resolutions/...









